Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) Stock Price & Overview
NASDAQ:IMDX • US68235C2061
Current stock price
4.18 USD
+0.17 (+4.24%)
At close:
4.18 USD
0 (0%)
After Hours:
The current stock price of IMDX is 4.18 USD. Today IMDX is up by 4.24%. In the past month the price increased by 11.17%.
IMDX Key Statistics
1-Month Range2.645 - 4.55
Current IMDX stock price positioned within its 1-month range.
- Market Cap
- 134.471M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.62
- Dividend Yield
- N/A
IMDX Stock Performance
Today
+4.24%
1 Week
+11.17%
1 Month
+11.17%
3 Months
-35.89%
Longer-term
6 Months -30.45%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
IMDX Stock Chart
IMDX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IMDX.
Chartmill TA Rating
Chartmill Setup Rating
IMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMDX. Both the profitability and financial health of IMDX have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IMDX Earnings
On March 26, 2026 IMDX reported an EPS of -0.72 and a revenue of 1.14M. The company missed EPS expectations (-197.53% surprise) and beat revenue expectations (285.06% surprise).
Next Earnings DateMay 18, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.72
Revenue Reported1.139M
EPS Surprise -197.53%
Revenue Surprise 285.06%
IMDX Forecast & Estimates
10 analysts have analysed IMDX and the average price target is 8.5 USD. This implies a price increase of 103.35% is expected in the next year compared to the current price of 4.18.
For the next year, analysts expect an EPS growth of 40.41% and a revenue growth -20.15% for IMDX
Analysts
Analysts78
Price Target8.5 (103.35%)
EPS Next Y40.41%
Revenue Next Year-20.15%
IMDX Index Membership
IMDX is currently included in the following stock indexes tracked on ChartMill.
IMDX Financial Highlights
Over the last trailing twelve months IMDX reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 63.18% compared to the year before.
Income Statements
Revenue(TTM)4.05M
Net Income(TTM)-50.22M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.99% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%62.69%
Sales Q2Q%-23.35%
EPS 1Y (TTM)63.18%
Revenue 1Y (TTM)115.58%
IMDX Ownership
Ownership
Inst Owners53.85%
Shares32.17M
Float25.65M
Ins Owners1.55%
Short Float %1.78%
Short Ratio1.84
IMDX Industry Overview
IMDX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
IMDX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMDX
Company Profile
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Company Info
IPO: 2015-12-30
INSIGHT MOLECULAR DIAGNOSTIC
2 International Plaza Dr., Suite 510
Nashville TENNESSEE US
Employees: 57
Phone: 19494097600
INSIGHT MOLECULAR DIAGNOSTIC / IMDX FAQ
What does INSIGHT MOLECULAR DIAGNOSTIC do?
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
What is the current price of IMDX stock?
The current stock price of IMDX is 4.18 USD. The price increased by 4.24% in the last trading session.
What is the dividend status of INSIGHT MOLECULAR DIAGNOSTIC?
IMDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMDX stock?
IMDX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of IMDX stock?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) operates in the Health Care sector and the Biotechnology industry.
How many employees does INSIGHT MOLECULAR DIAGNOSTIC have?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) currently has 57 employees.
Who owns INSIGHT MOLECULAR DIAGNOSTIC?
You can find the ownership structure of INSIGHT MOLECULAR DIAGNOSTIC (IMDX) on the Ownership tab.